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"A natureza é frequentemente escondida, algumas vezes dominada, mas 
raramente extinta." 
Francis Bacon 
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Abstract 
 
Worldwide, 3 million the women are diagnosed with breast cancer which is the 
most common malignancy in female gender. Breast Cancer is a heterogeneous 
disease and clinically it is evaluated using three markers: the estrogen receptor 
(ER), the progesterone receptor (PR) and the epidermal growth factor receptor type 
2 (HER2). 
The tumors that do not express any of these receptors are called triple-negative 
breast cancers (TNBC). TNBC represent approximately 20% of BC.  
These tumors constitute an important clinical challenge, as they do not respond 
to endocrine treatment and to anti HER2 directed therapy. As a group they harbor 
an aggressive clinical phenotype with early development of visceral metastases and 
a poor long-term prognosis. The only systemic treatment for TNBC is 
chemotherapy. Numerous experiments and trials have been done to try to 
understand what is targetable in TNBC and if so, if the clinical trials achieve their 
endpoints. Today, the trend in clinical practice is individualized treatment based on 
molecular biology markers of tumor and patient. 
 Lehmann et. al. attempted to characterize TNBC and put forward a 
microarray signature that divides these tumors in 6 groups, according to differential 
gene expression profiles: basal-like 1 (BL1); basal-like 2 (BL2); immunomodulatory 
(IM); mesenchymal (M); mesenchymal stem–like (MSL) and luminal androgen 
receptor (LAR). 
Androgen receptor is member of the steroid hormone receptor family, expressed 
in more than 70% of breast cancers and has been implicated in breast cancer 
pathogenesis. The role of AR is of particular interest in patients with TNBC. 
In this project, immunohistochemistry was used to characterize the AR 
expression in a consecutive cohort of TNBC cases from Hospital CUF Lisboa. The 
immunohistochemical panels of markers used to characterize this subgroup of 
breast cancer, along with AR, were the CK 5/6, p-cadherin, PHH3 and EGFR in an 
attempt to further characterize TNBC subtypes.   
Of all the TNBC cases, 56% (28/50) were CK5/6, 0; 22% (11/50) were CK5/6, 1+; 
12% (6/50) were CK5/6, 2+; and 10% (5/50) were CK5/6, 3+. In 96% (48/50) the 
expression of p-cadherin was positive while only 4% (2/50) was negative. 
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Regarding EGFR, 38% (19/50) were EGFR, 0; 26% (13/50) were EGFR, 1+; 24% 
(12/50) were EGFR, 2+; and 12% (6/50) were EGFR, 3+. The expression of AR was 
considered positive in 62% of cases of TNBC.  
We have known from the literature that AR status is a significant independent 
prognostic factor, although we cannot show this in this sample. In this study was not 
possible to implement the Lehmann classification because it was not possible to 
separate the different TNBC by Immunohistochemical staining into 6 different 
categories of the Lehmann classification. 
The functional role of AR in breast cancer remains unclear, further exploration of 
this area could expand the repertoire of potential treatments for patients with AR+ 
TNBC. 
Key words: Breast Cancer, Triple-negative Breast Cancer, prognostic markers, 
Immunohistochemistry, Androgen Receptor, Therapeutic Target. 
  
10 
 
Resumo 
 
O cancro da mama assume uma grande relevância na sociedade,  a sua 
incidência na Europa ocidental é de 90 novos casos por ano em cada 100.000 
habitantes e em Portugal é semelhante. O cancro da mama apresenta-se como 
uma doença heterogénea, não só clínica e histologicamente, como também no seu 
perfil de expressão genética. 
As modalidades terapêuticas têm evoluído, minimizando as cirurgias mais 
mutilantes, e a implementação de terapêuticas dirigidas, tanto anti-estrogénicas 
como anti-HER2. No seguimento deste conceito, a pesquisa de marcadores 
moleculares com potencial alvo terapêutico, assume um crescente interesse no 
seio da comunidade científica. Neste contexto temos como órfãos de terapêuticas 
alvo os tumores da mama triplo-negativo (TMTN), porque não expressam 
receptores de estrogénio, progesterona e do fator de crescimento epidérmico 
humano tipo 2.  
Lehmann et. al. apresentou uma classificação de seis subtipos histológicos 
para identificar os TMTN, com implicações genéticas, epidemiológicas, terapêuticas 
e práticas. Esta classificação foi obtida com recurso a expressão genética de 
milhares de genes, através de “microarrays”. Um dos objetivos deste trabalho é 
adaptar a classificação de Lehmann a uma técnica de utilização corrente nos 
hospitais que recorre a proteínas (anticorpos) pré-definidas com sistema de alta 
sensibilidade de deteção, a técnica de imunohistoquímica (IHQ). A classificação de 
Lehmann divide em 6 subtipos o cancro da mama triplo-negativo (CMTN). “Basal-
like” 1 e 2 (BL1 e BL2) correspondem a um grupo de tumores susceptíveis à 
quimioterapia clássica, porque eles têm mutações nos genes de reparação do 
ADN, estes são, também, os tumores que respondem bem à quimioterapia 
neoadjuvante e desenvolvem-se frequentemente em doentes portadores da 
mutação BRCA1 e BRCA2; em seguida o grupo com evidências genómicas de 
modulação imunológica, grupo de bom prognóstico; o terceiro grupo em que se 
divide ao cancro CMTN é o subgrupo classificado como mesenquimal. Estes 
tumores têm características mesenquimais e expressão de marcadores de células 
tronco, como a p-caderina. Estes tumores são quimioresistentes e poderão explicar 
a associação com mau prognóstico. Por fim o subgrupo de CMTN que expressam o 
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receptor de androgénio, descritos histologicamente, como tumores apócrinos, com 
tendência a recidiva local e que poderão ser susceptíveis à terapêutica com anti-
androgénios. 
Apesar de uma década de investigação clínica, continuamos sem ter qualquer 
modalidade terapêutica alvo para tratar os TMTN, recorremos ainda e só à cirurgia, 
quimioterapia (QT) e radioterapia (RT). Neste trabalho usámos um método auxiliar 
de diagnóstico na anatomia patológica que se tem mostrado de extrema 
importância, na prática clínica, que é o método da imunohistoquímica. O crescente 
uso desta técnica deve-se à necessidade de diagnósticos precisos para 
prognóstico e tratamento, principalmente de neoplasias. Vários avanços, 
nomeadamente um de fundamental importância, a chamada técnica de 
recuperação antigênica (sistemas de recuperação de epítopos através do calor 
(radiação ou calor húmido), e o uso de um número crescente de anticorpos 
disponíveis em tecidos fixados em formaldeído e incluídos em parafina, permitiram 
uma progressão na técnica. Estratégias utilizadas para obter uma melhor qualidade 
na marcação de anticorpos em tecidos pré- fixados, são também executadas pela 
IHQ. A utilização de enzimas específicas que amplificam uma grande quantidade 
de moléculas propiciadoras de visualização, são uma mais-valia pelo menor 
dispêndio do anticorpo primário, permitindo o aumento de diluições sem 
comprometer a intensidade de marcação antigénio-anticorpo. 
Neste trabalho será determinado, como objetivo principal a expressão do 
receptor de androgénio (RA), a partir do método imunohistoquímico. Na clínica o 
desdobramento de diferentes subtipos de CMTN não pode ser determinada, por 
esse motivo em conjunto com o RA, foram utilizados quatro anticorpos: 
citoqueratina 5/6 (CK5/6), o factor de crescimento epidérmico (EGFR), p-caderina e 
a fosfohistona H3 (PHH3). O nosso objetivo é dividir BL1 e BL2 através da 
avaliação do EGFR e CK 5/6 e um marcador de proliferação (PHH3); TMTN com 
fenótipo mesenquimal através da expressão de p-caderina; a infiltração linfocitária 
tumoral (ILT) permite a descrição de TMTN com fenótipo descrito como 
imunomodulador e os tumores que expressam receptores de androgénio, também 
chamados de tumores apócrinos, consequentemente com RA.  
O estudo abrange uma amostra de 80 casos de pacientes, previamente 
selecionados. Cerca de 80 casos de cancro da mama triplo negativo foram 
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analisados e feita a sua associação, posterior, com características clinico-
patológicas. Os casos CMTN foram conservados em blocos de parafina, 
selecionados consecutivamente no Serviço de Anatomia Patológica do Hospital 
CUF Descobertas de Lisboa.  
Nos casos de CMTN, a expressão de CK5/6 foi em 56% (28/50) de 0, em 22% 
(11/50) de 1+, em 12% (6/50) de 2+ e em 10% (5/50) de 3+. Em 96% dos casos de 
CMTN (48/50) a expressão de p-caderina foi positiva enquanto em apenas 4% 
(2/50) foi negativa. A expressão de EGFR foi em 38% (19/50) dos casos de 0, 26% 
(13/50) dos casos de 1+, 24% (12/50) dos cacos de 2+ e 12% (6/50) dos casos de 
3+. A expressão de RA foi elevada em 62% dos casos de CMTN. O RA é um fator 
de prognóstico independente significativo, embora não tenha sido possível 
demostra-lo nesta amostra. Neste estudo não foi possível implementar 
classificação de Lehmann à clínica porque não era possível separar os diferentes 
CMTN pelo método imunohistoquímico nos 6 subgrupos desta classificação. 
O papel funcional da RA no cancro da mama ainda não está claro. Um 
tratamento individualizado, tendo por base os novos conhecimentos moleculares, 
irá permitir a selecção de terapias efectivas com menores efeitos adversos. 
Todavia, mais estudos e ensaios clínicos são necessários para determinar o seu 
benefício. 
Palavras-chave: cancro de mama, cancro de mama triplo-negativo, 
marcadores prognósticos, imunohistoquímica, receptor de androgénio, terapêutica 
dirigida.   
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1. Introdution 
 
1.1 Female breast  
 
 The breast of mammals is important for milk production that ensures the 
survival of the newborn and the development of this species. 
 The breast consists of three tissue types: fatty tissue, connective tissue and 
mammary gland tissue. The glandular tissue is a specialized tissue whose function 
is to produce milk. The structures related to milk production are the lobules. Lobules 
are structures organized in 15 to 20 sections. In each lobule there is a secondary 
structure called lobe, where milk is produced. The structures responsible for 
directing the milk to the nipple are the ducts. The dark area of skin around the 
nipple is called the areola (figure 1) [1]. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Illustration of female breasts. The main components are the lobules 
and ducts, conductors and producers of breast milk, respectively; fat tissue, 
connective tissues and lymphatic vessels or blood. Adapted from National Cancer 
Institute (NCI) http://www.cancer.gov/images/cdr/live/CDR415520-750.jpg 
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The rest of the breast is composed of connective tissue (collagen and elastin), 
adipose tissue (fat) and an aponeurosis called Cooper ligament. The breast 
consists as well of skin, nerves, blood vessels, lymph vessels and lymph nodes [1]. 
The ducts are coated with 1 to 2 layers of cylindrical luminal cells. The lobular-
alveolar portion is coated with two layers of cuboidal cells with secretory capacity. A 
layer of myoepithelial cells is located in close contact with the basement membrane 
of the alveolar epithelium and the smaller ducts (figure 2) [1, 2]. These cells are 
sensitive to oxytocin, have clear portion of cytoplasm and oval nuclei and a part of 
dense cytoplasm containing myofibrils. Myoepithelial cells show positivity for 
immunohistochemical markers of epithelial origin as well as mesenchymal smooth 
muscle actin, p63, S100 protein and cytokeratins 5, 6, 14 and 17. These cells have 
contractile capacity and are responsible for the renewal of the luminal epithelium. 
The basal myoepithelial cells have high levels of type IV collagenase, with probable 
critical role in the renovation and remodeling of the basement membrane of the 
glands [3]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2A. Schematic representations of a duct. The luminal lineage can be 
further subdivided into ductal and alveolar luminal cells that line the ducts. In 
contrast, myoepithelial cells are specialized, contractile cells located at the basal 
surface of the epithelium adjacent to the basement membrane [2]. 
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Figure 2B. Histology of normal breast. It is possible to observe the benign 
lobule, surrounded by myoepithelial cells with an adjacent interlobular duct; 
H&E stain.  Adapted from Meenakshi Singh, MD © - Department of Pathology, 
Stony Brook University Medical Center. 
 
Mammary stem cells (MASCS) have assumed an important interest in organ 
development and maintenance of tissue homeostasis. These cells give rise to 
mature epithelium of either the luminal or myoepithelial lineage via a series of 
lineage-restricted intermediates. The profound expansion of mammary epithelium 
that occurs during puberty and pregnancy further implicates a stem-like cell with 
remarkable regenerative capability [2]. 
Several factors can influence the regulation of normal development and 
progression of carcinogenesis of the breast. Steroid hormones have a very 
important role, these produced by the ovaries, pituitary, endocrine pancreas, 
thyroid, adrenal cortex and adipose tissue. These hormones act through nuclear 
receptors or cell surface receptors and regulate the transcription of specific sets of 
genes [4]. 
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In normal breast tissue there are three main groups of cells, namely epithelial, 
myoepithelial/basal and stromal. Paracrine factors play a role in their interactions, 
and between the epithelial cells, autocrine mechanisms also play an important role.  
In normal conditions, the human body produces various types of hormones 
responsible, for example, by the growth of several types of cells. One of these 
hormones is estrogen which is responsible for female development, systematic and 
organized with cell multiplication. If this cell proliferation stimulated by several 
factors, including hormonal, occurs in an uncontrolled manner, this can result in the 
appearance of cancers - particularly breast cancer. With this assumption, one way 
to inhibit the growth of neoplastic mammary cells (cancer) is to eliminate the 
production of female hormones, especially estrogen and/or blocking the action of 
hormones on the cells. Only cells that have receptors for estrogen and/or 
progesterone in its surface are grow in response to a hormonal stimulus. The 
hypothalamus is the initial route of estrogen production, which "sends" the pituitary 
gland signals to order production of several hormones, including the gonadotropic 
hormones FSH (follicle stimulating hormone) and LH (luteinizing hormone). These 
hormones will act on the female sexual glands - ovaries – stimulating the production 
of estrogens. Estrogen may also be produced on a smaller scale, by another gland, 
the adrenal. Blocking this pathway production, in its different stages, is the main 
target of endocrine therapy for breast carcinoma. In all women the adipose tissue 
(fat cells) is a site of estrogen production. When in childbearing age (menstrual 
cycles), the production of female hormones is made primarily in the ovary, however, 
after menopause the adrenal gland is responsible for this function, producing 
hormones which will then be "converted" into estrogens in adipose tissue [1]. 
 Cancer results from an imbalance between of these interactions and the loss of 
control factors that promote cell survival (figure 3), activation of oncogenes, 
inactivation or loss of tumor suppressor genes, with participation of hereditary 
factors and exposure to factors that promote carcinogenesis. Breast carcinomas are 
characterized by uncontrolled and unregulated proliferation of epithelial cells (figure 
4), the disappearance of the myoepithelial cells, changes in the pattern of 
programmed cell death (apoptosis) and, sometimes, loss of certain epithelial 
characteristics, known as epithelial-mesenchymal transition (EMT) [5]. 
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Figure 3. Normal growth requires a balance between the activity of genes that 
promote and suppress cell proliferation. It also relies on the activities of genes that 
signal when damaged cells should undergo apoptosis. Cancer cells do not respond 
to many of the signals that control cellular growth and death. Cancer cells escape 
programmed cell death (apoptosis). Over time, these cells become increasingly 
resistant to the controls that maintain normal tissue. As a result, cancer cells divide 
more rapidly and become less dependent on signals from other cells.  In the late 
stages of cancer, cells break through normal tissue boundaries and metastasize 
(spread) to other organ sites in the body. Adapted from oncologiacuf. 
 
Both normal breast and neoplastic tissues are able to produce similar 
substances and hormones by its own cells, which act locally (paracrine hormones), 
and modulate the function of the epithelial, stromal and vascular/endothelial 
adjacent cells. The tumor cells are capable of producing polypeptides that act as 
autocrine growth hormone factors regulating gene transcription by acting in its own 
surface receptors [1]. Therefore, it is important to understand the origin of cancer 
and the factors behind this so that biological processes can help find targetable 
drugs for clinical success. 
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Figure 4. Examples of poorly differentiated breast cancer. The cancer cells change 
and become specialized. This description of breast can inform the grade of the 
cancer. As more the cells look like normal cells, the lower the cancer grade and the 
less normal they look, the higher the grade.  The histological images of breast 
cancer were provided by the Anatomic Pathology Laboratory, of Hospital CUF 
Descobertas.  
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1.2 What is Breast Cancer?  
 
 
Breast cancer is an uncontrolled growth of breast cells (figure 5). Cancer occurs 
as a result of mutations, or abnormal changes, in the genes responsible for 
regulating the growth of cells and keeping them healthy [6]. 
 
 
 
Figure 5. Hypothetical model of breast tumor progression. Schematic view of 
normal, in situ, invasive, and metastatic carcinoma progression.[7]. 
 
When normal mammary cells age or are damaged, they die naturally. When the 
cells loose this control mechanism and undergo changes in its genome they 
become cancer cells which do not die when they age or are damaged, and produce 
new cells that are not necessary in an uncontrolled manner, resulting in the 
formation of cancer [6, 8]. Another event that occurs is genomic instability 
(mutations, deletions, chromosomal rearrangements and amplifications), with an 
overall loss of normal tissue organization and possibly giving rise to metastases. 
The genomic stability is maintained by several modular components, which have a 
primary role in the suppression of cancer. The occurrence of inherited mutations in 
the major pathways of cell cycle control and repair of DNA damage causes an 
increase in susceptibility to breast cancer in women carrying these mutations 
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(BRCA1 and 2). On the other hand, mutations of the p53 gene are frequent in 
sporadic breast carcinomas. 
Breast cancer occurs when malignant tumors develop in the breast. These cells 
can spread by breaking away from the original tumor and entering blood vessels or 
lymph vessels, which branch into tissues throughout the body. When cancer cells 
circulate and seed in distant organs and damage tissues and organs, the process is 
called metastasis. The most common sites of cancer metastasis are (in alphabetical 
order )  the bone, brain, liver, and lung [9].  
 
1.3 Incidence 
 
Breast cancer is a problem for global public health and is the non-cutaneous 
malignancy more common in females, with increasing incidence in developed 
countries.  
About 12.7 million cancer cases and 7.6 million cancer deaths are estimated to 
have occurred in 2008 worldwide, with 56% of the cases and 64% of the deaths in 
the developing world [10]. 
Breast cancer is the second most common cancer in the world and, by far, the 
most frequent cancer among women with an estimated 1.67 million new cancer 
cases diagnosed in 2012 (25% of all cancers) [11].  
In Portugal BC remains the leading cause of cancer death in women with about 
5513 new cases per 100 000 persons per year [12]. 
More than half of these cases occur in industrialized countries. In the European 
Union, 367,000 new cases of BC were diagnosed in 2012 (about 28.8 % of cancer 
in women) [13]. The incidence of BC has increased more in developed countries but 
there has been an increase in incidence in developing countries, particularly in 
Africa, Latin America and Asia [14] [15]. 
Breast cancer is the leading cause of death in women between the ages of 25 
and 55 years in developed countries [16].  
The factors that contribute to the international variation in incidence rates are 
largely originated from differences in reproductive and hormonal factors and the 
availability of early detection services [17, 18]. 
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1.4 Breast Cancer Stages  
 
Clinical staging (designated cTNM or TNM) accordding to the AJCC system 
(American Joint Committee on Cancer) is based on all information available prior 
the first definitive treatment and includes the findings on pathological examination, 
imaging studies, operative findings on physical examination of the breast or other 
tissue [19, 20]. The extent of tissue examined pathologically for clinical staging 
includes tumor size (T), involvement of lymph nodes in the homolateral axilla (N) 
and whether the cancer is invasive or non-invasive. The presence or absence of 
distant metastases (M) is assessed through imaging [21]. Pathologic staging is 
based on a pathologist’s study of the lymph nodes and tumor tissue removed during 
surgery. The pathological classification requires the resection and examination of at 
least the low axillary lymph nodes (level I). If the lymph nodes are negative, but the 
number ordinarily examined is not met, classify as pN0. Often this is surgery to 
remove the cancer and nearby lymph nodes, but sometimes surgery may be done 
to just look at how much cancer is in the body and take out tissue samples. The 
pathological stage gives the health care team more precise information that can be 
used to predict treatment response and outcomes (prognosis) [21] (appendix I).The 
invasive nature of cancer is defined by the rupture of the basal membrane. The term 
"locally advanced" or "regionally advanced" is used to refer large tumors involving 
the skin of the breast, underlying chest structures, altering the shape of the breast 
and lymph nodes that are visible or palpable during clinical examination. 
 The stage of breast cancer is essential to determine prognosis and therapy.  
Breast cancer is classified into 4 stages (Table I) [1]. 
  Most breast malignancies arise from epithelial elements and are categorized 
as carcinomas. The invasive breast carcinomas consist of several histologic 
subtypes. Breast carcinomas are a diverse group of lesions that differ in 
microscopic appearance and biologic behavior, although these disorders are often 
discussed as a single disease. The in situ carcinomas of the breast are either ductal 
(also known as intraductal carcinoma) or lobular. This distinction is primarily based 
upon the growth pattern and cytologic features of the lesions, rather than their 
anatomic location within the mammary ductal-lobular system [22].  
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BC is also classified by its histopathologic characteristics [22] which are 
presented in table II and figure 6 .  
  
Figure 6. Histological images of different types of breast cancer. 
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 Table I: The stage of breast cancer. 
O 
This stage describes noninvasive (“in situ”) breast cancer. Ductal carcinoma in situ 
(DCIS) is an example of stage 0 cancer. 
I 
The cancer is completely inside the breast. 
IA: The tumors is 2 cm or smaller and has not spread outside the breast; 
IB: Small areas of breast cancer cells are found in the lymph nodes close to the 
breast and either. The tumors is 2cm or smaller or no tumors is found in the breast. 
 
II 
A stage II breast tumor is larger than a stage I tumor, but the cancer hasn't spread to 
a distant part of your body. 
IIA: The tumors are larger than 2cm but not larger than 5cm and there is no cancer in 
the lymph nodes or cancer cells are found in 1 to 3 lymph nodes in the armpit or in the 
lymph nodes near the breastbone. 
IIB: The tumors is larger than 2cm but not larger than 5cm and small areas of cancer 
cells are in the lymph nodes or The tumors is larger than 2cm but not larger than 5cm 
and the cancer has spread to 1 to 3 lymph nodes in the armpit or to the lymph nodes 
near the breastbone or The tumors is larger than 5cm and has not spread to the lymph 
nodes. 
III 
A stage III breast cancer, known as locally or regionally advanced cancer. This 
cancer may have spread to lymph nodes near your breast, those located under your 
arm or by your collarbone, but not to more-distant parts of your body. 
IIIA: tumors are either larger than 5 centimeters (2 inches) and have spread to one to 
three lymph nodes under the arm, or are any size and have spread into multiple lymph 
nodes. 
IIIB: tumor of any size has spread to tissues near the breast - the skin and chest 
muscles-and may have spread to lymph nodes within the breast or under the arm. 
IIIC: cancer is a tumor of any size that has spread: to 10 or more lymph nodes under 
the arm; to lymph nodes above or beneath the collarbone and near the neck; to lymph 
nodes within the breast itself and under the arm. 
IV 
The tumors can be any size, the lymph nodes may or may not contain cancer cells 
and the cancer has spread (metastasized) to other parts of the body such as the bones, 
lungs, liver or brain. 
Adapted from National Cancer Institution 
A 
Adapted from National Cancer Institution (NCI). 
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TableII. Breast Cancer Types. 
 
Invasive carcinoma of no special type (NST)  
Pleomorphic carcinoma  
Carcinoma with osteoclast-like stromal giant cells  
Carcinoma with choriocarcinomatous features 
Carcinoma with melanotic features 
Invasive lobular carcinoma  
Classic lobular carcinoma 
Solid lobular carcinoma 
Alveolar lobular carcinoma 
Pleomorphic lobular carcinoma 
Tubulolobular carcinoma 
Mixed lobular carcinoma 
Tubular carcinoma  
Cribriform carcinoma  
Mucinous carcinoma  
Carcinoma with medullary features 
Medullary carcinoma  
Atypical medullary carcinoma  
Invasive carcinoma NST with medullary features  
Carcinoma with apocrine differentiation 
Carcinoma with signet-ring-cell differentiation 
Invasive micropapillary carcinoma  
Metaplastic carcinoma of no special type  
Low-grade adenosquamous carcinoma  
Fibromatosis-like metaplastic carcinoma  
Squamous cell carcinoma  
Spindle cell carcinoma  
Metaplastic carcinoma with mesenchymal differentiation 
-Chondroid differentiation  
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-Osseous differentiation  
-Other types of mesenchymal differentiation  
Mixed metaplastic carcinoma  
Myoepithelial carcinoma  
Epithelial-myoepithelial tumors 
Adenomyoepithelioma with carcinoma  
Adenoid cystic carcinoma  
Rare types 
Carcinoma with neuroendocrine features 
Neuroendocrine tumor, well-differentiated  
Neuroendocrine carcinoma poorly differentiated (small cell carcinoma) 
Carcinoma with neuroendocrine differentiation  
Secretory carcinoma  
Invasive papillary carcinoma  
Acinic cell carcinoma  
Mucoepidermoid carcinoma  
Polymorphous carcinoma  
Oncocytic carcinoma  
Lipid-rich carcinoma  
Glycogen-rich clear cell carcinoma  
Sebaceous carcinoma  
 
  
Adapted  from WHO of Breast Tumors, 4th Edition [22]. 
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1.5 Clinical and histopathological prognostic factors 
 
Breast cancer is the most common cancer in women and its incidence is 
increasing. Breast cancer is a heterogeneous disease [23-26] which comprises a 
number of distinct biological entities that are associated with morphological and 
immunohistochemical outcomes and clinical characteristics [23, 26].  
The invasive breast carcinomas were for decades, only classified according to 
histological grade and hormone receptor expression [23]. The most important 
histopatological prognostic factors are the expression of ER and PR. These have 
enabled clinicians to treat BC in the last half a decade with anti-estrogens, 
significantly reducing BC mortality. Anti-estrogenic therapy is not toxic, well 
tolerated and cheap. Recently, after the success of clinical trials involving adjuvant 
trastuzumab, expression of the human epidermal growth factor receptor 2 (HER2) 
has become an integral part of the pathological workup for patients with breast 
cancer. HER2-positive breast cancer had worse prognosis compared with HER2-
negative tumors [27]. HER2  amplification is widely known to indicate an aggressive 
tumor behavior and a poor clinical outcome in breast cancer patients [28]. 
Simultaneously with the development of trastuzumab as a targeted therapy for 
breast cancer, some results of genome microarray began to be reported [29]. There 
are several types of clinical breast cancer, defined by amplification of specific 
markers. The over expression of steroid hormone (like estrogen and progesterone 
receptors) defines the most abundant type of breast cancer, accounting for about 
70%. (ER and PR positive) [24, 30, 31]. Therefore, several studies demonstrate that 
breast cancers can be divided according to hormone receptor (HR) expression 
(negative or positive) and/or epithelial cellular origin (basal or luminal), that have 
clinical implication [32]. Breast cancers can be divided into three main groups:  (1) 
hormone-positive breast tumors; (2) HER2 –positive breast cancer and (3) basal or 
triple-negative breast tumors (classification summarized in table III). The overlap 
between basal and triple negative BC is not complete [32]. Generally, there are 20% 
of classifications in either direction i.e. there are 20% of basal like BC that are not 
TNBC and similarly there are 20% of TNBC that are not basal-like BC. 
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 The tumors that are HR-positive are luminal A e B. This subtypes originate 
from inner (“luminal”) cells that line the mammary ducts, and they are dissimilar in 
their expression of HER2 (luminal A, which is negative and luminal B which is 
positive). Most carcinomas not related to genetic mutations, are characterized by 
the luminal A type [25]. The luminal B type is more likely to be lymph node-positive 
and to have high proliferation. Unlike the luminal A which tends to have a better 
prognosis, they often diagnosed in young women, the luminal B tumors tend to have 
a higher tumor grade, poorer prognosis and probably associated to genetic 
mutations. These phenotypes are associated with elevated gene expression by 
luminal epithelial cells, of molecules such as cytokeratins (CK) 7,8,18 and 19 [24, 
33, 34].  
The tumors that are HR-negative cannot be treated with anti-estrogens, are 
associated with a higher recurrence rate and a decreased overall survival. These 
tumors are more likely to be poorly differentiated, with higher histological grade [32]. 
HER2 tumors tend to be HR-negative and lymph node-positive. HER2 has been 
a major target for the development of the new cancer therapies in the last 20 years. 
Its greatest value as a predictive marker lies in the prediction of response to 
therapies that target HER2, such as trastuzumab (Herceptin) and with neoadjuvant 
anthracycline/taxane-based chemotherapy [35]. The HER2 oncogene amplification 
and concomitant overexpression of its protein, is currently implicated as an 
important prognostic biomarker in breast cancer [36].  
Basal-like tumors originate in the outer (“basal”) cells that line the mammary 
ducts. This subtype has a gene expression profile similar to the genes that are 
identified in normal basal/myoepithelial cells of the mammary ducts and acini. The 
gold standard for the identification of basal-like carcinomas as a particular class of 
molecular breast cancer in the clinic is TNBC [33]. 
 Their incidence has been estimated to be between 13% and 25% and they 
occur more frequently in young women and are associated with hereditary BRCA1-
related breast cancers. Their metastatic pattern includes early dissemination to the 
axillary nodes and to viscera (liver, lung, soft tissue and brain) and less frequently to 
bone. According to the most recent publications, this phenotype shows positivity for 
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CK5/6, CK14, receptor for epidermal growth factor (EGFR), p-cadherin, p63 and 
CK17 proteins that are expressed in the basal/myoepithelial cells [24, 30, 37]. This 
profile is associated with numerous genetic mutations [30]. 
The original microarray classification published in the year 2000 [24], defined a 
fourth group called normal-like tumors that account 6%-10% of all breast cancers. 
These tumors do not fall into any other categories, usually small, typically have a 
good prognosis and they are more common in postmenopausal than in 
premenopausal women. Perou et. al. [24] identified these group by increasing the 
expression of many genes known to be expressed by adipose tissue and other non-
epithelial cells. These tumors also showed strong expression of basal epithelial 
genes and low expression genes to the luminal epithelium. Nevertheless, it is still 
not clear if this distinction is of clinical value [24, 30]. 
 Estrogen receptor and progesterone receptor are the most studied markers in 
breast tissue. The results of ER and PR have been scored as ‘‘positive’’ and 
‘‘negative’’ although receptor protein concentration (in biochemical assays) and the 
percentage of cells stained and staining intensity (in Immunohistochemical assays) 
range widely [26]. Several studies report that the ER/PR status is an independent 
predictor of outcome in breast cancer tumors. The association of this status with the 
mortality is observed in tumors ER+/PR-, ER-/PR+, and ER-/PR-tumors compared 
to women with ER+/PR+ tumors. The prognostic usefulness of the expression of 
steroids hormone receptors is partially independent from the association in clinical 
characteristics and demographic characteristics of tumors. The higher relative 
mortality identified among ER-/PR- patients with small or low-grade tumors, raise 
the question of whether there may be a beneficial role for adjuvant chemotherapy in 
this population [38].  
The problem of steroid receptor testing inaccuracy and non reproducibility is 
extremely serious because we are inadequately classifying BC but also because we 
are depriving women of anti-estrogenic therapy. For the determination of prognosis 
and therapy of BC some other proteins such as HER2, Ki-67, p53 are sought in 
addition to hormone receptors[39]. When BC does not express ER, PR and HER2 it 
will not benefit from the currently available receptor-targeted systemic therapy and 
these tumors are called TN. This study will be focused on TNBC. 
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One of the most important challenges ahead is to identify specific molecules 
alterations in tumors and to validate targeted therapies for them. This is sometimes 
called precision/personalized therapy [24]. With the development of primary and 
secondary resistance to hormonal treatment, new substances and new patterns of 
association with blockers of growth factor receptors were created, enhancing the 
effect of drugs and recovering the responsiveness to endocrine therapy. Some of 
these substances are aromatase inhibitors (anastrozole, letrozole), antagonist of 
estrogen and progesterone receptors (fulvestrant), pan-EGFR inhibitors 
(GW572016), mTOR inhibitors (rapamycin RAD001-inhibit tumor growth central 
controller and angiogenesis), anti-HER2 (trastuzumab), and drug that blocks cell 
growth by stopping mitosis (cell division) [40].   
Table III. Subtype ( hormone and HER2 receptor status) 
 
 
Luminal A 
  
(ER+ or PR+ or both, HER2-) 
Luminal B  (ER+ or PR+ or both, may be HER2+) 
HER2  (ER-, PR-, HER2+) 
Basal-like  (ER-, PR-, HER2-) 
Triple-negative tumors  (ER- , PR-, HER2-) 
Normal breast-like  Tumors that do not fall into any the foregoing 
categories 
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1.6 Risk factors 
 
Risk factors for breast cancer are age, race/ethnicity, age of menarche and 
menopause, multiparity, radiation mantle before Hodgkin lymphoma, oral 
contraceptive use and body mass index.  
Family history of breast cancer, particularly having one or more first degree 
relatives with breast cancer (although most women with breast cancer do not have 
a family history of the disease) increases the risk of breast cancer. Inherited 
mutations in breast cancer susceptibility genes account for approximately 5% to 
10% of all cancers of the female breast and an estimated 4% to 40% of all male 
breast cancers, but are very rare in the general population (much less than 1%). 
Most of these mutations are located in BRCA1 and BRCA2 genes, although 
mutations in other known genes have also been identified [18] [31]. 
Increased risk of hormone receptor–positive tumors was also associated with 
postmenopausal obesity, which probably increases estrogen exposure via different 
mechanisms. Obesity is associated with increased aromatization of circulating 
androgens to estrogens in adipose tissue and reduced levels of sex hormone 
binding globulin, thereby increasing both total and bioavailable estrogens [31]. A lot 
of studies summarized the risks of hormone receptor-positive and hormone 
receptor-negative BC. The majority of know BC risk factors are associated with 
hormone receptor-positive disease. Risk factors for HR-negative  BC are young 
age, African origin and BRCA1/2 germline mutation [31]. In addition, the effect of 
hormone-related risk factors on hormone content within the breast is unknown. 
Although many factors have been shown to contribute to elevated systemic levels of 
estrogens, a relationship between high serum levels and the development of 
hormone receptor positive tumors has not been established [31].  
Potentially modifiable risk factors that can be minimized include overweight, 
lack of exercise, smoking cigarettes, eating unhealthy food, alcohol consumption.  
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Two drugs (tamoxifen and raloxifene), have been approved to reduce breast 
cancer incidence in high risk women. Raloxifene appears to have a lower risk of 
certain side effects, such as uterine cancer and blood clots; however, it is only 
approved for use in postmenopausal women. 
Women and society have the empowerment to lower BC risk by making 
healthiest lifestyle options possible. 
 
 
1.7 Diagnosis Tests 
 
Several tests can help distinguish a benign (noncancerous) lump from a 
malignant (cancerous) tumor. Because malignant and benign lumps tend to have 
different physical features, imaging tests such as mammography (figure 7) and 
ultrasonography can often rule out cancer. The only way to confirm cancer is to 
perform a needle aspiration or a biopsy to be analyzed. Before BC screening was 
implemented, breast cancer detection was limited to diagnosis based on physical 
examination by the woman herself or her physician. The concept of screening is to 
detect non palpable lesions.  
When breast cancer is found at an early stage, the cure rate is high, the aim of 
screening is to detect non palpable disease and increase survival. Such cancers 
may be detectable only in mass population screening endeavors. Mammograph 
was suggested by Salomon, a German pathologist in 1913, as a modality to detect 
breast cancer and in 1959, Egan at the MD Anderson Hospital in Houston published 
results from a series of 1000 cases emphasizing the detection of non palpable 
lesions. In a practical, cheap and feasible, mammography has been implemented 
as an important method for early detection of BC, reducing mortality.  
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Figure 7. Mammography of locally 
advanced breast cancer. Mammogram 
shows dark areas of normal fatty breast 
tissue and lighter areas are dense breast 
tissue that includes ducts and lobes. The 
whitest area is the most dense, 
indicating a tumor (breast cancer), 
indicated by a red arrow. This picture 
was provided by Hospital CUF 
Descobertas) 
 
 
 
Ultrasound testing works by transmitting high-frequency sound waves, inaudible 
to the human ear, through the breast. The sound waves bounce off surfaces in the 
breast (tissue, air, fluid) and these "echoes" are recorded and transformed into 
video or photographic images. Breast ultrasound is a procedure that may be used to 
determine whether a lump is a cyst (sac containing fluid) or a solid mass which 
might be cancer (figure 8). If the lump is found to be a cyst, fluid is typically 
withdrawn from it using a needle and syringe (a process called aspiration). If clear 
fluid is removed and the mass completely disappears, no further treatment or 
evaluation is needed. 
Ultrasound can also be used to precisely locate the position of a known tumor to 
help guide the needle during a biopsy or aspiration procedure. Ultrasound helps 
confirm correct needle placement. 
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Figure 8. Ultrasound images of a malignant breast lesion. A. shows a typical 
malignant nodule that is taller than wide. B. Some of the nodules may reveal a 
branching pattern, indicated by white arrows [41]. 
 
The two main tests used to diagnose breast conditions are mammograms and 
ultrasounds. Magnetic resonance imaging (MRI) is used in some cases, usually 
along with one of the other two tests. 
A biopsy may be performed when an abnormal finding in the breast is 
discovered during a mammogram, ultrasound, or physical examination. The method 
recommended will depend on how large the breast lump or abnormal area where in 
the breast it is located, how many lumps or abnormal areas such as suspicious 
calcifications are present. The types of breast biopsies include: ultrasound-guided 
core biopsy, stereotactic biopsy, open excisional biopsy and sentinel node biopsy. 
 Imaging studies alone cannot provide a specific diagnosis on which to base 
treatment decisions. The breast biopsy is a procedure, which confirms whether the 
tissue is cancerous or precancerous. The table IV summarizes the tests that may be 
used to diagnose breast cancer or for follow-up testing after the cancer has been 
diagnosed.  
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Table IV. Tests and diagnostic procedures for breast cancer. 
Imaging tests 
Mammography  
Untrasounds 
MRI 
Surgical tests Biopsy 
Molecular testing of 
the tumor 
ER and PR, HER2; KI-67 
Tests and 
procedures used to 
stage breast cancer 
-Blood tests, such as a complete blood count 
-Mammogram of the other breast to look for signs of cancer 
-Breast MRI 
-Bone scan 
-Computerized tomography (CT) scan 
-Positron emission tomography (PET) scan 
Figure 9. Image of breast biopsy system.  
Adpated from http://www.mammotome.com/images/supplement/BiopsySystem1.png 
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1.8 Treatment 
 
Treatment involves conservative surgery (surgical removal of the tumor and 
surrounding tissue) or mastectomy (surgical removal of the breast). The tumor size 
and breast size grade are the patient characteristics that will be important to choose 
type of treatment to adopt.  
Numerous studies have shown that for early breast cancer (cancer that has not 
spread to the skin, chest wall, or distant organs), the long-term survival for women 
treated with breast-conserving surgery plus radiotherapy is similar to those treated 
with mastectomy. For women undergoing mastectomy, significant advances in 
reconstruction techniques provide several options for breast reconstruction, 
including several different options on the timing of the process. 
In women with early stage disease, the sentinel lymph node biopsy, a 
procedure in which only the first lymph nodes to which cancer is likely to spread due 
to lymph node anatomical drainage system are removed, has a lower chance of 
long-term side effects and is as effective as a full axillary node dissection, in which 
numerous nodes are removed, to determine whether the tumor has spread beyond 
the breast.  
Treatment may also involve radiation therapy, chemotherapy (before or after 
surgery), hormone therapy or targeted therapy.  
Tumor cells viable after neoadjuvant chemotherapy (NAC), which is 
chemotherapy administered before surgery, are a population of cancer cells that is 
intrinsically resistant to chemotherapy. These tumor cells likely reflect the 
component of micrometastatic disease, which is responsible for distant metastases, 
and is unlikely to be sensitive to adjuvant chemotherapy, if so metastases will one 
day become evident. Specifically, this phenomenon has been observed in patients 
with TNBC who have residual disease after NAC [40]. 
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2. Triple-negative breast cancer (TNBC) 
 
TNBC has a growing recognition by oncologists, pathologists and geneticists 
since 2005, when it began to be referred by the term "triple-negative" [42]. TNBC 
comprises 12 to 17% of BC cases. This terminology reflects a heterogeneous 
population with a much more complex molecular transcriptome than is suggested by 
the triple-negative (TN) immunohistochemical (IHC) expression [43].  Furthermore 
this definition is misleading because it tells us what these cancers are not and not 
what they are, it is a negative definition. 
TNBC is a distinct subtype defined by the lack of immunohistochemical 
expression of the estrogen receptor (ER) and progesterone receptor (PR), human 
epidermal receptor growth factor 2 (HER2) amplification. TNBC generally has 
expression of genes normally found in the basal, myoepithelial cells or normal 
breast [25, 42-44] .  
The frequency of the triple-negative breast cancer increases with age, it 
comprises approximately 15% to 20% of all breast cancers [25, 45] although TNBC 
are more common than ER positive BC in younger patients (<50 years) and African 
American women [42, 44]. TNBC is associated with an advanced stage, increased 
risk of visceral disease and worse outcome. Several studies have been carried with 
the purpose of demonstrating these associations [24, 25, 37, 46-48]. These tumors 
are generally larger in size, are of high histological grade (III) [23], with lymph node 
involvement at diagnosis, and are biologically more aggressive with worse 
prognosis [24]. The majority of TNBC are grade III or poorly differentiated, infiltrating 
ductal carcinoma not otherwise specified (IDC NOS). The few remaining cases are 
rare histological types like adenoid-cystic, medullary, apocrine, metaplastic or 
inflammatory BC [23]. 
 The aggressiveness of this subtype of cancer is illustrated by the fact that the 
peak risk of recurrence is between the first and third year of follow-up in patients 
diagnosed with TNBC and most deaths occur in the first 5 years after therapy. 
When compared with patients who have other subtypes of breast cancer [24]. Less 
than 30% of women with metastatic TNBC survive five years and all die of the 
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disease, despite having undergone adjuvant chemotherapy and subsequently 
chemotherapy for advanced disease [24] [49]. 
Patients with triple negative breast cancer are more likely to develop distant 
metastases earlier than non-triple negative breast cancer patients, develop brain 
metastases sooner [28]. The prevalence of genetic mutations among women with 
TNBC referred for genetic counseling is high and differs significantly by 
ethnicity/race and age [45]. 
This molecular subtype of breast cancer is characterized by a profile of gene 
expression similar to that found in basal/myoepithelial cells. The multiplicity of 
names reflects an underlying uncertainty about the true nature of this entity.  
 The breast cancer literature includes a large number of reports on prospective 
clinical trials examining the effects of endocrine therapy, chemotherapy, targeted 
therapy combinations, but none has validated a specific systemic therapy for TNBC 
[42]. Although effective tailored therapies have been developed for patients with 
HER2 positive or hormone receptor positive, chemotherapy is the only modality of 
systemic therapy for patients with BC that lack the expression of these three 
markers [44] [43]. 
One of the first molecular insights into TNBCs was the finding that they are 
likely to arise in patients with germline mutations in the BRCA1 gene and have gene 
expression profiles (GE) similar to those tumors which are not TNBC but arise in 
germline BRCA1 mutated women [44]. Germline BRCA1 or BRCA 2 mutations 
among women are the most frequent hereditary breast cancer syndromes and are 
associated with a 90% lifetime risk of developing BC. Studies have shown the 
prevalence of BRCA mutations in women with TNBC is high, therefore the finding of 
a woman with a TNBC and positive family history of BC is a reliable indicator of 
possible BRCA germline mutation [45]. BRCA1 behaves as an important gene in 
DNA repair of double strand DNA breaks, similarly contributing to the maintenance 
and stability of DNA [44]. Among a population of patients with TNBC referred for 
genetic counseling and genetic testing between 2000 and 2012, the prevalence of 
BRCA mutation carriers exceeded 30% [45]. 
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2.1 TNBC subtypes 
 
There are several studies that research the molecular profile that distinguishes 
subtypes of TNBC. Until recently, most studies on TNBC aimed to identify markers 
that separate TNBC from other BCs, and it is likely that these studies identify 
molecules that differentiate amongst subtypes of TNBC. 
Since 2005, when the widespread use of anti-HER2 therapy started to change 
HER2 positive BC, TNBC finally became the only subtype of BC for which there is 
no targeted therapy. This is a very important unmet need in BC. Since then a lot of 
experiments and clinical trials have been done to try to understand what is 
targetable in TNBC, and if the clinical trials meet their endpoints, so we might 
validate usable drugs for daily practice. Besides the therapeutic challenge, TNBC 
entails a diagnostic challenge and Lehman et. al. after several experiments have 
put forward a convincing classification of six subtypes with histological, genetic, 
epidemiological, therapeutic, and, therefore, practical implications (appendix II). 
TNBC subtypes were characterized on the basis of differential GE and gene 
ontologies and subsequently labeled TNBC as follows: basal-like (basal-like 1 
(BL1); basal-like 2 (BL2)); immunomodulatory (IM); mesenchymal (M); 
mesenchymal stem–like (MSL); luminal androgen receptor (LAR) [44]. 
The top biological processes present in the BL1 subtype are cell cycle and cell 
division components and pathways. Elevated DNA damage response (ATR/BRCA) 
pathways accompany the proliferation pathways in the BL1 subtype. Increased 
proliferation and cell-cycle checkpoint loss are consistent with the elevated 
expression of the DNA damage response genes observed. The highly proliferative 
nature of this subtype is further supported by the finding of high Ki-67 mRNA 
expression (MKI67). Enrichment of proliferation genes and increased Ki-67 
expression in basal-like TNBC tumors suggest that this subtype would preferentially 
respond to antimitotic agents such as taxanes (paclitaxel or docetaxel). The BL2 
subtype displays unique gene ontologies involving growth factor signaling as well as 
glycolysis and gluconeogenesis. Likewise, the BL2 subtype is uniquely enriched in 
growth factor receptor expression such as EGFR, MET (proto-oncogene, receptor 
tyrosine kinase), and EPHA2 (member of the ephrin-A receptor subfamily of 
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receptor tyrosine kinases). This subtype has features suggestive of 
basal/myoepithelial origin as demonstrated by higher expression levels of p63 and 
MME (CD10) [34]. 
The IM subtype is enriched in immune cell processes. The IM signaling is 
evidenced by immune signal transduction GE, in addition to immune cell-surface 
antigens, cytokine signaling, complement cascade, chemokine receptors and 
ligands, and antigen presentation genes. This subtype of TNBC substantially 
overlaps with the gene signature for medullary breast cancer, a rare, histologically 
distinct form of TNBC that despite its high-grade histology is associated with a 
favorable prognosis. 
The M subtype (M and MSL subtypes) displays a variety of unique gene 
ontologies that are heavily enriched in components and pathways involved in cell 
motility. The difference between the M and MSL subtypes is that the MSL subtype 
expresses high levels of proliferation genes. This subtype was associated with a 
highly dedifferentiated type of breast cancer called metaplastic breast cancer, which 
is characterized by mesenchymal/sarcomatoid or squamous features is 
chemoresistant and, therefore, carries severe prognosis.  
The LAR group is the most distinct among the TNBC subtypes. This subtype is 
ER negative, but gene ontologies are heavily enriched in hormonally regulated 
pathways including steroid synthesis, porphyrin metabolism, and androgen/estrogen 
metabolism. Others have previously described a breast cancer subgroup 
expressing AR termed molecular apocrine and this BC has good prognosis. 
The identification of different subtypes of TNBC had focused on regulatory 
molecules, both extracellularly the immune system and at the level of the plasma 
membrane, a gene set comprised epithelial growth factors. The immune regulation 
has previously been proposed to play a role in BC and, in particular the ER positive 
BC. Intracellularly, these gene products bind to the molecules proliferation that 
control, such as cyclins. The activation of the immune response may preclude a 
good prognosis; this would be similar to the good prognosis associated with 
immune activation in melanoma, ovarian and kidney cancer.  
P53 expression is a predictor of shorter time to relapse in independent 
populations diagnosed with TNBC. Similarly, increased expression of EGFR 
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appears to predict adverse prognosis in TNBC. In the latter report, loss of c-Kit and 
BRCA1 expression were also reported to be predictive of poor outcome in TNBC. 
The cell lines representative of the TNBC subtypes display different sensitivities 
to a variety of agents, and importantly, these differences can be attributed to distinct 
expression of cellular components and presence of mutations in key oncogenes and 
tumor suppressors [44].  
In the seventies, the early tests of the presence of AR protein in breast cancer 
specimens were performed, by the McGuire laboratory [50]. Currently, most of the 
studies were performed using specific anti-AR antibodies in IHC studies. This study 
will focus more on the expression of this protein in samples of patients with TNBC.  
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2.2 Androgen receptor  
 
Steroid hormone receptors are ligand-activated transcription factors that 
regulate eukaryotic gene expression and affect cellular proliferation and 
differentiation in target tissues. The AR gene is more than 90 kb long and codes for 
a protein of 919 amino acids that has three major functional domains, as illustrated 
in figure 10 [51]. 
 
 
 
 
 
 
 
Figure 10. Human androgen receptor gene. The human androgen receptor 
protein is encoded by 8 exons (1-8). Similarly to other nuclear receptors, the protein 
consists of several distinct functional domains: the NH2-terminal domain (NTD), the 
DNA-binding domain (DBD), the hinge region and the ligand binding domain (LBD) 
[51].  
Throughout a woman's life, the production of steroid hormones is prolonged and 
varied. During the fertile period of a woman’s life, estrogen and progestogens 
(progesterone and 16-OH progesterone) are secreted by the ovaries. Estrogen is 
the most important hormone in terms of mitogenic and morphogenic capacity, 
however it is secreted at low levels, unlike the progestogens that were abundantly 
secreted. The precursors required for the synthesis of estrogen in the ovaries are 
androgens (testosterone and androstenedione).  
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Androgens are also secreted by both the ovaries and adrenal glands and 
circulate in a similar estradiol concentration during the pre-ovulatory peak and in a 
higher during the remainder of the menstrual cycle. Androgens are sexual steroids 
which are dominant throughout a woman's life. After menopause, there is a survival 
adaptation to an environment with a low concentration of estrogen. This adaptation 
requires increased capacity of local estrogen synthesis and increased cellular 
response to these hormones. Together, this change may cause the epithelial cell to 
have increased levels of aromatase and of receptor coactivators of estrogen. 
Estrogen drives carcinogenesis because it induces cell survival. The endogenous 
sex steroids have been implicated in the development of breast cancer with 
evidence of increased risk among women who had early menarche and decreased 
in women who experience early natural menopause or had a bilateral ovariectomy 
at young age.  
 
 
 
 
 
 
 
 
Figure 11. Synthesis of steroid hormones at menopause. Both adrenal and ovarian 
androgens produce low power, mainly androstenedione and dehydroepiandrosterone 
sulfate (DHEA-S). Enzymes 17-hydroxysteroid dehydrogenase and aromatase are 
widespread in peripheral tissues, including brain, liver, adipose tissue and the 
pathological and normal breast epithelium. Aromatase catalyzes the conversion of 
androgens to estrogens. Estrogen content of breast cancer cells during menopause is 
even higher than in tumors in premenopausal women. As the tissue of breast cancer 
also contains sulfatase activity, DHEA-S also acts as a precursor to estrogen. (Image 
adapted from http://www.glowm.com/resources/glowm/cd/graphics/figures/v5/0380/05.gif) 
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The androgen receptor is a member of the family of nuclear receptors that are 
dependent on the binding of transcription factors. The AR has a higher affinity for 
dihydrotestosterone (DHT) than for testosterone, the two most potent natural 
androgens. 
 The process of binding of the hormone results in a conformational change in 
the molecule that promotes the AR to spill cytosolic heat shock proteins, and 
translocate to the nucleus. Once bound to a hormone, AR is able to form 
homodimers that are associated with chaperones and nuclear coactivators and is 
the active form of the receptor. The probability of accumulating, uncorrected DNA 
replication errors and mutations, which are the basis of estrogen-related 
tumorigenesis thus increases. Cells adapted to a low estrogenic environment 
increase the number of cell cycles per year, these changes include androgen 
aromatization to produce estradiol which is mitogenic in epithelial breast cells. 
Hormone-related breast carcinogenesis after menopause possibly is a 
consequence of subtle changes that allow the epithelial cells to survive in a low 
estrogenic environment. Older age at diagnosis has previously been reported in 
patients with AR-positive BC [44].  
Besides being able to act as an estrogen precursor, androgen can directly act 
on epithelial breast cells by activating the androgen receptor which modulates a 
number of genes at the transcriptional level. 
Information on of AR expression in breast cancer is sparse. Studies have 
focused on the role of androgens and the androgen receptor and they have 
demonstrated that androgens can lead to proliferation of AR expressing breast 
cancer cell lines and promote tumor formation in animal models. AR is a marker of 
good prognosis and this effect appeared independent of coexpression of ER. New 
drugs targeting AR have been used in cases of BC. Despite an association with 
good outcome, targeting of breast tumors expressing AR may be beneficial, similar 
to the effects of pharmacologic targeting of ER (for example, bicalutamide, a non-
steroidal anti-androgen).  
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3. Objective 
 
The main purpose of this study consisted in the evaluation of the expression of 
androgen receptor in triple-negative breast cancer. The sample was collected at 
Hospital CUF Descobertas, Lisbon, and consisted of all consecutive TNBC treated 
and followed in the Institution in the years between 2005 to 2012.  
TNBC due to its heterogeneous profile presents a specific problem in detecting 
targets for systemic therapy.  
Thus, in this study, we had a second objective. The relevance of the Lehmann 
classification of TNBC cannot be ascertained because this classification has not 
been adapted to IHC. We used, together with the androgen receptor, the following 
antibodies: CK5/6 (cytokeratin 5/6), p-cadherin, EGFR (epidermal growth factor 
receptor) and PHH3 (phosphohystone H3) to further separate TNBC.  
Gene expression profiles signature derived from the most differentially 
expressed genes found in the TNBC training set and used to predict which TNBC 
subtype was best-fit for each of the tumors in the validation set. 
 In this study, distinct genes ontologies were used to each TNBC subtype. BL1 
and BL2 subtypes were determined through the assessment of EGFR and CK5 /6 
and a proliferation marker PHH3. The BL1 subtype expressed higher levels of basal 
cytokeratin expression; enriched in cell cycle, cell division components and 
pathways and the highly proliferative nature. The BL2 subtype displays unique gene 
ontologies involving growth factor signaling. Expression of p-cadherin was used for 
the identification of mesenchymal. This subtype displays a variety of unique gene 
ontologies that are heavily enriched in components and pathways involved in cell 
motility; epithelial-mesenchymal transition is associated. The immunomodulatory 
TNBC subtype will be assess through the evaluation of TIL (tumor infiltration 
lymphocytic). And for last, the LAR (luminal androgen receptor) subtype was 
determined by the androgen receptor. 
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4. Materials and methods  
 
Patients diagnosed with triple-negative breast cancer, between the years 2005-
2012, were included in this study from Hospital CUF Descobertas e Hospital Infante 
Santo.  
The initial sample included 80 cases of TNBC. Because of lack of information 
from the patients and paraffin blocks from the Hospital CUF Infante Santo (patients 
with an incomplete record and/or patients without tissue available to be studie), the 
sample includes only patients from Hospital CUF Descobertas and comprises 66 
patients with TNBC.  
 
4.1 Clinical-pathological method 
 
Clinicopathological parameters including age, type of surgery, tumor size, 
histological grade, node involvement, adjuvant treatment, disease free survival 
(DFS) and Overall survival (OS) were reviewed. 
The patients' age categorized in  less than  35 years, from 35 to 50 years, from 
50 to 65 years and over  65 years.   
Ppathological data correspond to the size of the tumor, lymph node involvement 
and histological grade were also analysed. The size of tumor was categorized as < 
2cm, between 2cm and 5cm, >5cm the diameter and/or not determined. For lymph 
node involvement was described as positive or negative involvement, and/or not 
determined. The histological grade was classified in 1 (well), 2 (moderate), 3 
(poorly) and/or not determined (Scarff-Bloom-Richardson grading system). 
Adjuvant treatment refers to the administration of both chemotherapy (CT) and 
radiotherapy (RT) treatments. 
DFS was defined as the interval (mouths) from primary surgery data until the 
first relapse of disease.  
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OS was the time, in months, from the date of the primary surgery data to the 
time of breast cancer related death. 
The information from patients was collected from electronic patient records and 
hospital charts. Before study initiation, Institutional ethics committee approval was 
obtained. 
 
4.2 Histopathological method 
 
All the material collected had be fixed in 10% formaldehyde included in paraffin 
(type 6, Richard said AllScientic ®), following the usual methodology. After the 
inclusion, slices of 2,5  -3 μm thick were performed in a manual Minot microtome, 
manual (RM2255 leica Microssystems). Then, the sections were placed on slides 
and held drying in an oven (60 min at 60ºC or overnight at 37ºC). After drying in a row 
in decreasing alcohol concentration (70%, 96% and absolute alcohol -100%), 
proceeded to staining with Hematoxylin (Harris) and Eosin (alcoholic), about 40min-
1h. 
The histopathologic review was made by pathologist with experience in breast 
cancer at the Pathology Department, Hospital CUF Descobertas.  
  
Figure 12. Minot microtome and cold plate 
used in the histology laboratory. 
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4.3 Immunohistochemical method 
 
The blocks for Immunohistochemical analysis of patients with TNBC subtype 
were obtained from the Pathology files, Hospital CUF Descobertas. After obtaining 
high quality paraffin blocks, the study comprised only 50 cases. The experimental 
work was conducted at the Faculty of Medicine, University of Lisbon (FMUL) at the 
Institute of Pathology, in collaboration with the Technical Catarina Isabel Talina. 
After obtaining the blocks of patients with triple-negative breast cancer, 2μm 
thick slices were made and placed in adherent SuperFrost®Plus slides, which then 
are putted in the oven to dry for 60 min. 
Immunohistochemistry is a set of methodologies that use antibodies as specific 
reagents that are able to identify and connect with tissue constituents that act as 
antigens. This connection allows locating and identifying the presence of various 
substances in cells and tissues by means of color that is associated with the 
antigen-antibody complexes formed [52]. 
The possibility of combining a marker with an antibody without causing any 
damage to the specific connection established between antibody and antigen 
makes this technology area heavily used in Pathology. This provides the 
microscopic observation of the location where is the antibody and hence the 
antigen. Apart from the quality of the antibody, the marking quality also depends on 
the pre-analytical phase (highlighting tissue fixation and processing), the recovery of 
antigenic epitopes and sensitivity of the detection system. 
In this study, the immunohistochemical method used was the method of indirect 
polymer. This method applies a primary antibody directed against the desired 
antigen, and subsequently applies a polymer to which they are coupled "secondary" 
antibody substances and enables visualization of HRP (Horseradish Peroxidase). It 
is a quick and easy method, showing a decrease of error factors. 
This method enables amplification of weak signals i.e. proteins of low 
abundance can be visualized. It is however, a very expensive method.  
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The method of indirect polymer uses a dextran polymer, not containing avidin or 
biotin, then the markup nonspecific does not occur in various tissues. A solution of 
3,3-diaminobenzidine tetrahydrochloride (DAB) was used as chromogen agent.  
Dextrans are high molecular weight molecules of approximately 500kDa, with 
high solubility in water and low toxicity/immunogenicity. These molecules are used 
as the internal skeleton of the polymer. Rarely bind to poly (1,6-α-D-glucose), which 
makes them resistant to cleavage by endogenous glycosidases of the cell.  
Commercially, these molecules which are presented in the form of a highly 
flexible polymer agglomerates in solution become very extensible spirals. This 
compound is readily soluble in water and electrolyte, being colorless, transparent 
and highly stable solutions. This type of polymer affects large and encompasses 
approximately 100 molecules of HRP and 20 of the type secondary antibodies goat 
anti-mouse or goat anti-rabbit, all of these molecules bound directly to the skeleton 
of the active dextran (figure 14). 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Representation of the polymer dextrano technique. 
Adapted from IHC Amadeu BF [52]. 
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Table V shows the different tissues used as positive controls for different 
antibodies. 
Initially several preliminary experiments were performed to optimize the primary 
antibody (Table VI), for the method of antigen retrieval and incubation time for the 
clearance technique.  
Breast cancer tissue were immunohistochemically stained for cytoqueratin 5/6, 
androgen receptor, p-cadherin, phosphotistone H3 (PHH3) and epidermal growth 
factor receptor as previously according to the suppliers data sheet (Abcam, 
Company- Cambridge Science Park  and Cell Marque Corporation-Supplies primary 
antibodies to Ventana Medical Systems®). 
Table V. Controls for CK 5/6, Androgen receptor, P-cadherin, EGFR and PHH3. 
Antibodies Positive controls 
CK5/6 Mesotheliome 
Androgen receptor Prostate 
P-cadherin Tonsil 
PHH3 Tonsil 
EGFR Lymph Node with metastase 
Table VI. Log referring to clone, type, cellular location and dilution of the antibodies 
according to the mark. 
Antibody Brand Clone Species Cell Location Dilution 
CK5/6 Cell Marque D5 & 16B4 
Mouse 
monoclonal 
Cytoplasmatic 1:200 
AR Cell Marque SP107 
Rabbit 
monoclonal 
Nuclear 1:100 
P-caderin Abcam Ab140338 Policlonal Membranar 1:1000 
PHH3 Cell Marque N/A Policlonal Nuclear 1:100 
EGFR Abcam  EP38Y Monoclonal Membranar 1.100 
 
CK5/6 = cytokeratin 5/6; AR = Androgen receptor; P-caderin; PHH3 = phosphohystone H3; EGFR =epidermal 
growth factor receptor. 
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The immunohistochemical analysis followed the following protocol:  
Dewaxing: Place slides in the sections marked with study at 60°C for 60min. Allow 
to dry prior to antigen retrieval for 20 minutes (90°C)  
 Antigen retrieval: place the rack with the blades filled by antigen retrieval buffer PT 
module (15ml Buffer Cell Marque Trillogy R 1: 400 in 1485 ml of distilled water) in 
Electric Pressure camera to immunohistochemistry for 1 hour on high / low 
pressure; at the end, removed and allowed to cool approximately 37 min in distilled 
water.  
Dehydrate until absolute alcohol ( 70%, 96%, 100%)  
Blocking of endogenous peroxidase: the blades were passe by 4 ml bath of 
hydrogen peroxide diluted in 200mL methanol for 15 min, rinse in distilled water.  
Washes with TBS: two washes with TBS, 5 min each.  
Dilution of antibodies that will be used: with the solution (antibody diluents; 
Diamond) as the blades are in phase antigen retrieval.  
Application of the primary antibody (for 60 minutes)  
Washes with TBS: two washes with TBS, 5 min each.  
Immunoenzymatic labeling method (HRP): 10 minutes applies an amplifier twice, 
five minutes each; applies then the polymer for 10 minutes twice, five minutes each.  
Revelation with DAB ((3,3′-Diaminobenzidine tetrahydrochloride hydrate) HRP 
substrate; Cell Marque chromogens) for 3 minutes solution 50 ml of chromogen 
more 1000 ml substrate.  
Washing with tap water to remove excess  
Counter staining with Mayer's Hematoxylin for a few seconds  
Wash in warm water  
Dehydration of the cuts to the absolute alcohol - xylene.  
Clearing and mounting the slides in xylene 
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5. Statistic Analysis 
 
The statistical analyzes was performed using SPSS for Windows (Version 17). 
Survival analysis was performed with the Kaplan-Meier method. The Kaplan-Meier 
estimate is also called as “product limit estimate” and it is the simplest way of 
computing the survival over time in spite of all the variability associated with cancer 
patients and cancer follow-up. In clinical trials, the effect of an intervention is 
assessed by measuring the number of subjects whose survival increased or 
decreased after that intervention over a period of time. The survival curve provides 
a measure of mortality of patients with TNBC.  
The results of the immunohistochemical analysis of the expression of Ck 5/6 
were defined by intensity of staining and percentage of tumor cells. The expression 
of stained cells was divided into four categories: absence or weak labeling (0); weak 
staining and less than 1/3 of the cells (1+); moderate intensity staining of 2/3 of cells 
(2+) and strong staining of 3/3 (3+). The same was applied to the methodology of 
EGFR protein (score 0-3+). The marking was checked for EGFR membrane 
labeling. The expression of p-cadherin was staining according to positivity or 
negativity of the marked tissue. Expression of the androgen receptor was 
determined by nuclear expression of this protein (≥ 10%).  
Proliferation index is calculated the counting of PHH3 by expression of nuclear 
tumor cells. The percentage of tumors cells expressing the proliferation marker 
PHH3 determined the growth rate of tumors. The proliferation index was calculated 
by the total number of PHH3- positive nuclear profiles. Due to poor tissue fixation, 
some cases were excluded.  
Inflammatory infiltration was classified in absent, moderate, slight, intense and 
not determined. 
  
52 
 
6. Results 
 
The clinical characteristics of the patients included in this study are presented in 
table VII. We studied samples of 66 patients with TNBC obtained from Hospital CUF 
Descobertas, Lisbon, between 2005 and 2012.The clinical chart data were reviewed 
and analyzed. The majority of patients were middle aged between 50 and 65 years 
old. The median age was 60 years. About 89% of patients underwent surgery. The 
majority of these patients also presented a tumor grade II or III. The tumor size had 
a mean 2,1 cm and a median of 1,8 cm. 
TNBC patients had positive axillary nodal involvement was found 74%. In total, 
44% of the patients underwent chemotherapy and radiotherapy, 79% underwent 
chemotherapy.  
Subsequently, the median follow-up time for the time diagnosis until the disease 
free survival (DFS) was 12 months (range, 0-24months). Overall survival for that 
death population was 3 years (range, 1-6 years). TNBC phenotype was associated 
with poorer outcome in terms of overall survival and disease-free interval when 
compared to publish cohorts of BC patients. 
The Kaplan-Meier method was used to estimate time-to-event functions. 
Approximately 75% of patients remain without evidence of disease (Figure 14A). 
The calculation was made in a range of time in months, we found a median of 12 
months and a mean of 11 months to relapse of TNBC. The calculation of OS 
(Figure 14B) was made in a range of time, in years, with a median of 3 years and a 
median of 3.28 years from the diagnosis to date of death. DFS and the OS were 
obtained in a confidence interval of 95%. 
Most patients received additional neoadjuvant chemotherapy following FEC 
(Fluorouracil (5-FU), epirubicin, cyclophosphamide) plus docetaxel. 
The most common site of initial relapse was bone. Other sites involved in 
relapse are lymph nodes, central nervous, system lung and liver.  
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Note: Percentage (%) indicates the percentage within the subgroup. 
 
Table VII. Patient and Tumor Characteristics Associated with TNBC. 
 
 
No. of patients ( %) 
Patient or tumor Features TNBC ( N= 66) % 
Age At Diagnosis (y) 
 
  
<35 1 2% 
35-50 13 20% 
50-65 28 42% 
>65 24 36% 
Surgery 
  
Positive 59 89% 
Negative 1 2% 
Not determined 6 9% 
Nodal involvement 
  
Positive 49 74% 
Negative 0 0% 
Not determined 17 26% 
Tumor Grade 
  
1 (well) 1 2% 
2 (moderate) 14 21% 
3 (poorly) 45 68% 
Not determined 6 9% 
Tumor size (cm) 
  
≤ 2 34 52% 
2 < cm ≤ 5 18 27% 
≥ 5 4 6% 
Not determined 10 15% 
Adjuvant treatment 
  
CT / RT 
  
Yes 29 44% 
No 6 9% 
Not determined 31 47% 
Disease Free Survival ( DFS), months, (Range) 12 ( 0-24) 
Overall Survive, years, (Range) 3 (1-6) 
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A 
Figure 14. A. Disease-free survival curve for patients with TNBC. 
Probability of survival estimated using the Kaplan-Meier method. B. 
Overall-survival curve of patients with TNBC. Probability of survival 
estimated using the Kaplan-Meier method. 
B 
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After analyzing available clinical data, the tissue samples were reviewed and 
tested for CK5/6, AR, p-cadherin, EGFR and PHH3 staining. The clinical 
pathological status of TNBC used CK5/6, AR, p-cadherin, EGFR and PHH3 which 
are summarized in Table VIII.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table VIII. Expression of CK5/6, AR, p-cadherin, 
EGFR and PHH3 in 50 cases of TNBC. 
Antibodies No. of patients (%) 
 
Ck5/6 
0 
1+ 
2+ 
3+ 
 
 
56% ( 28/50) 
22%(11/50) 
12% (6/50) 
10%(5/50) 
 
AR 
<10% 
>10% 
 
 
62%( 31/50) 
38%( 19/50) 
 
P-cadherin 
Positive 
Negative 
 
96%(48/50) 
4%(2/50) 
 
EGFR 
0 
+1 
+2 
+3 
 
38%(19/50) 
26%(13/50) 
24%(12/50) 
12%(6/50) 
 
PHH3 
≥5% positive 
<5%negative 
 
80% (40/50) 
20%(10/50) 
. 
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Of all the TNBC cases, 56% (28/50) were CK5/6, 0; 22% (11/50) were CK5/6, 
1+; 12% (6/50) were CK5/6, 2+; and 10% (5/50) were CK5/6, 3+. The expression of 
AR was calculated by upper or lower than 10% of the labeled cells staining. In some 
cases with higher expression of AR, we attributed scores of 50%, 90% and/or 
100%. Thus, there were 62% of cases being lower than 10% and 38% of cases 
where there was more than 10% AR labeling. In 96% (48/50) the expression of p-
cadherin was positive while only 4% (2/50) was negative. The 38% (19/50) were 
EGFR, 0; 26% (13/50) were EGFR, 1+; 24% (12/50) were EGFR, 2+; and 12% 
(6/50) were EGFR, 3+.  
In this work we assessed proliferation through labeling our samples with the 
PHH3 antibody. PHH3 is a core histone protein, which together with other histones 
forms the major protein constituents of the chromatin in eukaryotic cells. 
Immunohistochemical studies performed with anti-PHH3 antibody have shown that 
the antibody detects specifically the core protein histone H3 only when is 
phosphorylated at serine 10 or serine 28. The phosphorylation of histone H3 is a 
rare event in interphase cells but is a process almost exclusively occurring during 
mitosis. Studies have also revealed no phosphorylation on the histone H3 during 
apoptosis. Therefore, PHH3 can serve as a very effective mitotic marker. 
A Ki-67 cut-off point of 15% was defined according to the experience of different 
pathologists as well as national and international recommendations at present [53]. 
In this study, less than 5% staining with the antibody is considered low for the 
proliferation index and greater than or equal to 5% is considered high for PHH3 
proliferation index. About 80% (40/50) of the sample of TNBC have a high nuclear 
staining of PHH3 and around 20% (10/50) are considered low. 
Inflammatory infiltration (IF) has been considered as a likely prognostic factor in 
malignant neoplasms, and in this study was classified as absent, slight, moderate, 
intense and not determined (table IX). This rating was assessed in the samples 
used for PHH3 staining with the analysis of the antibody PHH3. In 34% (17/50) of 
TNBC cases IF was classified as absent; in 16% (8/50) of TNBC cases IF was 
classified as moderate; in 22% (11/50) of TNBC cases IF was classified as slight 
and in 8% (4/50) TNBC cases IF was classified as intense inflammatory infiltration. 
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The remaining cases were called “not evaluable” for above mentioned reasons and 
represent 20% (10/50) of cases TNBC.  
 
 
 
 
 
 In this series of TNBC, basal phenotype was defined by expression of CK5/6, 
EGFR and PHH3 in tumor cells; mesenchymal phenotype of TNBC was defined by 
expression of p-cadherin protein; immunomodulatory phenotype of TNBC was 
defined by the evidence of lymphocytic infiltration and luminal receptor androgen 
phenotype was defined for the expression of AR. The table X summarizes TNBC 
subtypes and markers used in this study. 
 
 
 
 
 
 
 
 Microphotographs showing the morphology and immunohistochemical results 
for CK5/6, p-cadherin, EGFR, AR and PHH3 in breast tissue (figures 15-18). 
Immunohistochemical expression of CK5/6 was observed by cytoplasmatic staining 
(figure 15), p-cadherin (figure 16A) and EGFR (figure 16B) positive cells were 
observed by membranar staining and the AR (figure 17) and PHH3 (figure 18) 
observed by nuclear staining.  
Table IX. Lymphocytic infiltrate 
absent 17 34% 
slight  11 22% 
moderate 8 16% 
intense 4 8% 
Not available 10 20% 
Table X. TNBC subtypes and markers. 
Subtype Markers 
Basal -like CK5/6, EGFR, PHH3 
Mesenchymal (M,MSL) P-cadherin 
Immunomodulatory Lymphocytic infiltration 
Luminal androgen 
 receptor 
AR 
58 
 
 
 
 
 
 
 
 
  
Figure 16. (A) Immunohistochemical preparation of samples from patients with 
TNBC which shows the p-cadherin expression (40x).  (B) Immunohistochemical 
preparation of samples from patients with TNBC, which shows EGFR 
expression (40x). 
A 
B 
A.1 
Figure 15. (A) Immunohistochemical preparation of samples from patients 
with TNBC which shows the cytoplasmic expression of CK5/6 (40x).  
 
A 
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A 
A.1 
Figure 17. (A) Microphotographs showing AR expression (20x); 
(A.1, A.2). AR expression (40x); intense nuclear staining. 
A.2 
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Figure 18. PHH3 nuclear expression (40x). This cell proliferation marker here is 
positive in about 70% of the nuclei. It is a protein present in all cells which are in cell 
division and absent in G0 cells that do not divide cycle. PHH3 is a very effective 
mitotic marker. 
 
  
D.2 
A 
A.1 
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7. Discussion 
 
Breast cancer is a heterogeneous disease. Currently, breast cancer, relies on 
traditional prognostic factors including nodal status, tumor histological grade and 
primary tumor size, in addition on expression to ER, PR and HER2. The molecular 
identification has allowed the classification of subtypes of BC, however it remains 
difficult to predict response to therapy. Surgery, radiotherapy and chemotherapy 
individually or in combination, are the only available modalities for patients with 
TNBC. Patients with TNBC do not benefit from hormonal or trastuzumab-based 
therapies, because of the loss of target receptors such as ER, PR and HER2 [32]. 
TNBC tumors were mainly of high histological grade, high mitotic index and 
were found more frequently in old age women [32]. The most common histological 
types were carcinomas of no specific type, metaplastic and apocrine carcinomas, 
the majority of these tumors were grade III. 80%-90% of TNBC truly have the basal 
molecular phenotype, which is known to be associated with worse OS [25].  
This study shows the expression of five antibodies in cases of TNBC. These 
results attempted to apply to IHC the Lehamnn classification of TNBC subtypes 
performed in with genomics. 
The expression profile of cytokeratin intermediate filaments is used in clinical 
practice and has been applied for the differentiation of metastatic tumors of 
unknown origin and currently is being used with interest to mark the cells of the 
mammary gland [54]. Cytokeratins have an important role in the cell motility, cell 
membrane support, forming pathways for the transport of organelles and other 
elements in the cytosol, under constant rearrangements that can produce cell 
movements [55] [56]. Cytokeratins type II (CK5 and 6) and type I (CK14) stain basal 
and / or myoepithelial cells, while antibodies to cytokeratins type II (CK7 and 8) and 
type I (CK18 and 19) are associated with the luminal/glandular epithelial cells of the 
breast [54]. 
The expression profile of cytokeratin CK5/6 and CK14 is interesting for studying 
BC. These markers have been used in the identification of basal-like TNBC. Since 
the early work of Sorlie et. al. [30], the terminology and definition (morphological 
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and genomic) of basal-like cancers, remains controversial. Nielsen et. al. [37] 
proposed an immunohistochemical panel of four antibodies (ER, HER2, HER1 and 
CK5/6), although there is still no exact correlation with the genomic expression 
profiles determined by DNA microarrays. Recent European studies propose the use 
basal expression of cytokeratins (CK5/6 and/or CK/14) as the defining element of 
the phenotype of basal-like BC. To identify the basal TNBC, Rakha et. al. recently 
proposed to employ the criteria [57]: expression of CK5/6 and/or CK/14. In this 
study, for characterization the basal TNBC we chose CK5/6, EGFR and PHH3 
markers. 
 In this work, the expression of CK5/6 is negative in 56% of the case is positive 
in 44% of these cases. The expression of EGFR is positive in 62% of cases and the 
expression of PHH3 is high (80% the cases of TNBC). This finding allows us to 
suggest that the subtype that is more dominant in the set, the group BL2 because 
the high percentage of EGFR and proliferation marker. 
EGFR is a cell surface protein which, is activated by binding of epidermal 
growth factor (EGF), through tyrosine-kinase activity. EGFR gene amplification has 
been described in different tumors, especially in the central nervous system, lung 
and stomach [58]. Recently, protein expression of EGFR has been described in 
breast carcinomas especially in metaplastic carcinoma, which although less 
frequent, is inserted into the differentiation pathway of progenitor/myoepithelial cells 
of the mammary carcinogenesis [59] [60]. EGFR immunoreactivity in TNBC IDC 
(triple-negative breast cancer, invasive ductal carcinoma) of the breast emerges as 
a clinically relevant prognostic parameter. Recently reported studies already 
indicated that EGFR expression is associated with significantly worse DFS in early 
breast cancer [61].  A significant proportion of the patients with TNBC IDC might 
have tumors concomitantly showing intratumoral necrosis [28], as well as EGFR 
and basal cytokeratin immunoreactivity [46]. This may explain why these closely 
associated factors are not all independently predicting DFS or OS when taken 
together in the full regression models [61]. 
The adherens-type junctions are related in normal development, to the role of 
cell sorting during embryogenesis and in the maintenance of specific organ and 
adult tissue architecture. Any disorders involving dysfunction of classical 
63 
 
cadherins/catenins are related to various disease states, including cancer. P-
cadherin is transiently expressed in various tissues during development and its 
permanent expression is limited to adult epithelial tissues, at cell-cell boundaries. 
The use of particular markers that are expressed only in basal cells (or 
myoepithelial cells) of the mammary gland have led to a recently developed strategy 
to improve the diagnosis, prognosis and treatment in these tumors. In various 
human tumors, p-cadherin expression is altered, but its role in the carcinogenic 
process remains unclear because it behaves differently depending on the cancer 
cell model studied [62]. 
 The expression of p-cadherin is well established as an indicator of poor 
prognosis in human breast cancer [62]. P-cadherin stimulated our interest in 
studying its role in TNBC and the results were consistent with what was reported in 
literature. The p-cadherin is over expressed in TNBC, 96% of cases were positive 
for this marker.  
Several studies analyze lymphocyte infiltration in breast cancer and in fact they 
show that inflammatory cell infiltration of tumors contributes either positively or 
negatively to tumor invasion, growth, metastasis, and patient outcomes, which 
creates a conundrum when examining mechanisms of action. TIL (tumors infiltrative 
lymphocytes) has shown to be predictive of prognosis in breast cancer and it has 
been taking emphasis. The correlation between intratumoral immune responses 
and clinical outcomes in TNBC is potentially related to the role of immune cells in 
the activity of cytotoxic chemotherapeutics. In mice, chemotherapy with 
anthracyclines requires priming of IFNγ- producing CD8+ T cells [63]. In humans, 
correlative studies have reported that high intratumoral levels of IFNγ and CD8+ T 
cells [64], or TILs, are associated with better clinical responses to anthracycline-
based chemotherapy [65]. 
The immunomodulatory subtype of TNBC was determined by the expression of 
lymphocytic infiltration. This assessment in our work was not technically optimized 
and was not planned because many of the cases don´t have good tissue 
preservation. Evaluation of TIL is thus compromised.   
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More recently, attention has focused in androgens and androgen receptor (AR) 
as prognostic markers and therapeutic targets in breast cancer [66]. The 
significance of AR expression is less well characterized when compared with the 
prognostic significance of ER and PR expression, in breast cancer and their roles in 
predicting therapy. 
The implication of androgens in breast carcinogenesis was tested in animal 
models and this showed that testosterone in combination with estrogen can induce 
mammary carcinomas. The mammary gland density values were significantly higher 
in animals treated with testosterone alone or in combination with 17β-oestradiol 
than in those treated with 17β-oestradiol alone or in controls. The strong expression 
of androgen receptor in epithelium increased the amount of perialveolar and 
interlobular connective tissue and the proliferation rate of fibroblast-like cells in the 
stroma and had decreased the surrounding adipose tissue. All these changes were 
blocked by simultaneous implantation of flutamide, indicating that androgens play a 
crucial role in the process despite the absence of androgen receptors in stromal 
cells [67].  
 Several studies have focused on ER-positive tumors and have shown some 
association between AR status and disease-free survival, as well as response to 
endocrine therapy, but these findings have not been confirmed in AR positive and 
ER negative [68] [69, 70]. The ER-negative tumors characteristically have a poorer 
prognosis and are thought to respond poorly to endocrine therapy [71]. 
In one of the largest studies of AR status in breast cancer has found a highly 
significant association between AR status and survival, that remained significant 
even when taking ER status into account [72]. AR status was a significant 
prognostic factor for disease-free survival in univariate analysis, in multivariate 
analysis, only lymph node status, tumor size, and ER status were independent 
prognostic variables [68].   
Curiously, in our study, the expression of androgen receptor is low. The sample 
reveals 38% positive case for AR expression. This observation shows that AR is not 
the most frequently expressed marker. Although statistical significance was lacking 
in our univariate analysis, a larger sample and additional research may help clarify 
whether AR status is a significant independent prognostic factor. The functional role 
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of AR in breast cancer remains unclear, further exploration of this area could 
expand the repertoire of potential treatments for patients with TNBC.  
In this sample, IHC identified the subtypes of TNBC. The biologic validation of 
all the cases studied by conventional immunohistochemical techniques is laborious, 
expensive and time consuming. Given the high degree human error and difficulties 
to maintain its performance under identical conditions of temperature, concentration 
of reactants, even with the automation of some of the steps involved, there are 
numerous reports of conflicting results in the literature.  
Additional markers [24, 32] are being sought to further refine those 
classifications, especially in patient subgroups such as TNBC, whose response 
therapy cannot be predicted accurately by conventional parameters. In this study 
we obtained the expression of the five markers in our work the expression of a 
single marker cannot be quantified due to very frequently overlap by the others 
markers. In clinical practice, this is what happens. Lehamnn starting from an 
analysis of gene expression was able to individualize each marker and accurately 
classify the subtypes of TNBC. It is important to note, the level of difficulty in clinical 
practice to get a correct diagnosis, for better targeted therapeutics. TNBC is an 
unclarified entity, despite all the advances in trying to respond to this subtype of BC, 
it requires more research for better pathological, clinical and therapeutic 
clarification. 
Clinical trials evaluating the efficacy of certain receptors as targets for new 
therapeutic drugs have been performed, for example [40]:  
1- Anti-EGFR and C-kit [37] the expression of EGFR has been reported in 66% 
of BC patients with TNBC tumors cells and basal-like tumors cells. Clinical trials 
evaluating the efficacy of humanized anti-EGFR monoclonal antibodies and EGFR 
tyrosine kinase inhibitors in TNBC are currently under way; 
2-  In vitro studies have indicated that breast tumor cells from BRCA1 germline 
mutations are extremely sensitive to a damaging high importance of these agents is 
based on the BRCA1 pathway and DNA repair dysfunction seen in TNBC, which 
may confer enhanced sensitivity to agents that damage DNA; Cells null for BRCA1 
were shown to be incapable of repairing DNA double strand breaks [73];  
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3-  The agents that inhibit PARP1 have successfully completed phase II and 
phase III studies have begun [74]. The PARP1 inhibitors effectively impair the ability 
of cancer cells to repair DNA damage causing the death on these cells;  
4- Several genes have been reported to be amplified in TNBC. Many 
components of the proliferation pathways (Ras, MEK/ ERK) are overexpressed or 
mutated in cancer cells [40]. This can represent potential targets for TNBC. Genetic 
aberrations, such as gain of 1q, 3q, 7q, 8q and 10p and loss of 4p, 5q, 17p and 8p, 
have also been found in tumors arising in BRAC1 mutations carriers [75].  
 
In this study we predicted that TNBC tumors could belong to the mesenquimal 
subtype by high expression of p-cadherin and/or, a sizable part of the sample could 
belong to the basal-like subtype, through the expression of CK5/6, EGFR and 
PHH3. However this observation is inconclusive, given the fact that we obtained a 
lot of overlap between the classifiers we used. The scientific advances with a view 
to clinical practice should move in this direction as future goals to better 
characterize subtypes of TNBC.  
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8. Conclusion  
 
Since the sequencing of the human genome in 2000, the ability to predict and 
treat cancer has increased. Genomic date will be generated for all tumors in the 
future and we will know the genetic abnormalities between normal and tumor tissue, 
to be able to design effective targeted therapies [76].  
In the era of precision medicine, enabled by affordable next generation 
sequencing oncologists are often faced with patients requiring treatment and reports 
describing mutations, amplifications or deletions of oncogenes and tumor 
suppressor genes. The vision for the treatment of TNBC focuses on potential 
molecular targets and biomarkers that can be designed or analyzed for the 
prediction of response of TNBC patients to chemotherapy, radiotherapy and/or 
biologic targeted therapy. 
TNBC is characterized by the absence of ER, PR and HER2 expression these 
are very aggressive tumors with poor prognosis. This aggressiveness is best 
illustrated by the fact that the peak risk of recurrence is between the first and third 
years and the majority of deaths occur in the first 5 years following therapy. An ideal 
scenario would allow hypotheses around resistance pathway activities, optimal 
target identification and target combination strategies to be studied driven by 
pharmacodynamic and short term efficacy biomarker endpoints in accessible 
residual disease tissue and in blood. Trial designs and platform approaches that are 
in development to address these points [77]. 
Currently applied regimens are mostly based on a combination of 
anthracyclines and taxanes which suggests again the importance of further 
comparative studies evaluating the efficacy with these standard approaches based 
or other therapies in TNBC[74].  
It is apparent that patients with AR positive TNBC tumors are likely to 
demonstrate limited benefit from the current standard-of-care chemotherapy 
regimens for TNBC, and then it will be necessary to study with targeted 
investigational combination treatments [71]. 
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The molecular apocrine breast cancer subset has recently been identified. LAR 
cells are in part dependent on AR signaling as siRNA-mediated AR knockdown or 
pharmacological inhibition of AR by bicalutamide (CDX) greatly decreases cell 
viability and tumor growth- hormonally responsive cancers. CDX as a single agent 
in metastatic AR positive, ER/PR negative breast cancers (NCT00468715/ 
TBCRC011) has demonstrated some efficacy with a clinical benefit rate of 19% [78]. 
Tumors with AR expression are more likely to harbour PIK3CA mutations. The 
combination of AR antagonism and PI3K inhibition has found an additive or 
synergistic effect on AR positive TNBC in cell growth. AR is described as a 
biomarker for the selection of TNBC patients for clinical trials, which would 
investigate the efficacy of therapeutic combinations that simultaneously target AR 
and PI3K [79]. 
TNBC patients when treated with anthracyclines, cyclophosphamide and 
taxanes had overall pathological complete response (pCR) of 28% and patients with 
the AR subtype had a poor response with only 10% achieving pCR prior to surgery. 
Clinically, AR negative patients have a higher likelihood of achieving pCR with 
neoadjuvant chemotherapy than AR positive patients [80]. 
The effective inhibition of sex hormones can be a therapeutic target in patients 
that present AR expression. Seen that oestrogens and androgens act together in 
mammary carcinogenesis, with estrogen could possibly be the predominant initiator 
whereas the androgen acts as a great promoter of carcinogenesis of the mammary 
gland [67].  
Paracrine influences of factors secreted by epithelial cells, such as transforming 
growth factor (TGF) β is an important growth factor involved in epithelial–stromal 
interaction. The important point concerning TGF-β1 in epithelial–stromal interaction 
in carcinogenesis is its various effects on tumors host tissue, particularly with 
respect to angiogenesis, immunosuppression, fibroblast activation and restructuring 
of the tumors extracellular matrix. Although TGF-β1 is a powerful inhibitor of normal 
epithelial cell proliferation, its effect on epithelial tumor cells is slight in adenomas 
and totally lost in carcinomas. T cell stimulation may act through the AR on 
mammary epithelial cells. Upon stimulation by T cells, the epithelial cells secrete 
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TGF-β1, which can act on stromal cells to stimulate growth of the stroma. This may 
explain growth of the stroma on androgen stimulation [67]. 
  Emerging technological advances in proteomics and transcriptomics requiring 
complex bioinformatics approaches in the future will pose further challenges and 
exciting opportunities. AR positive TNBC tumors are likely to demonstrate limited 
benefit from the current standard-of-care chemotherapy regimens for TNBC. The 
combination therapy would be the first trial in which TNBC patients are divided 
based on AR expression and, as a result, aligned to a targeted investigational 
combination treatment.  
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9. Future perspectives 
 
As future perspectives, it will be necessary to increase the study sample to 
clarify a few points, namely to be able to generate better statistical, pathological, 
clinical and therapeutic results. 
A major challenge would bring to the routine clinical practice a more 
technological and accurate approach, as did Lehamnn. 
 Analysis of a genomic profile could classify the various subtypes of BC and a 
better treatment would be applied, including hormone therapy. To validate genomic 
results with IHC, the use of tissue matrix arrangements tissue microarrays (TMA) 
has greatly facilitated the rapid and reproducible verification of the relevant 
candidate genes and molecules. IHC is a relatively simple technique, whose 
validation over conventional techniques is increasingly consolidated, having quickly 
spread in major global research and clinical centers. 
 TMA and IHC have the potential to generate predictive and prognostic markers 
in data sets of large numbers of samples.   
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 Adapted  from AJCC Cancer Staging Manual..Breast. 7th ed. New York, NY: 
Springer, 2010 
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II 
Adapted from Lehmann, B.D., et al. 
 
Figure 3 
GE patterns within TNBC subtypes are reproducible. Heat maps showing the relative GE (log2, 
–3 to 3) of the top differentially expressed genes (P < 0.05) in each subtype in the training set (left) 
and the same differentially expressed genes used to predict the best-fit TNBC subtype of the 
validation set (right). Overlapping gene ontology (GO) terms for top canonical pathways in both the 
training and validation sets as determined by GSE-A are shown to the right of the heat maps. 
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